IceCure Medical Ltd. (ICCM) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and thank you for standing by. Currently, all of the participants are in listen-only mode. After management discussion, there will be a question-and-answer session. Please be advised that today's conference call is being recorded. I would now like to turn the conference over to Michael Polyview. Please go ahead. Thank you, Operator, and welcome to IceCure Medical's conference call to review the financial results as of and for the three months ended March 31, 2026. and provide an update on recent operational highlights. You may refer to the earnings press release that we issued earlier this morning. Participating on today's call are Ice Care Medical's CEO, Al Shamir, the company's VP of sales, North America, Shad Good, and our guest, Dr. Richard Fine, a key opinion leader in the treatment of breast cancer, a breast surgeon, and Ice III investigator who has published and presented Ice III data and is active in hands-on trainings and symposia for Cryoablation and the Treatment of Early-Stage Breast Cancer. Before we begin, I will now take a moment to read a statement about overlooking statements. This call and the question and answer section that follows it contains overlooking statements within the meaning of the SAPAR provisions of the Private Securities Litigation and Reform Act of 1995 and other federal securities laws. Words such as expects, anticipates, intends, plans, believes, seeks, and estimates And similar expressions or variations of such words are intended to identify pro-local statements. For example, we're using pro-local statements in this presentation when we discussed ISEER's accelerating commercial momentum and growing engagement for ProSense, recurring revenue potential, converting growing interest into system sales and installations. T...